Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206546
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other | (98) | (6) |
| Net cash used in operating activities | (9,537) | (28,484) |
| Investing activities | ||
| Purchases of property and equipment | (796) | (1,259) |
| Purchases of marketable securities | (38,863) | (50,654) |
| Proceeds from maturities of marketable securities | 48,802 | 77,486 |
| Net cash provided by investing activities | 9,143 | 25,573 |
| Financing activities |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Adaptive Biotechnologies's capex?
- Adaptive Biotechnologies (ADPT) reported capex of $796K in Q1 2026.
- How has Adaptive Biotechnologies's capex changed year-over-year?
- Adaptive Biotechnologies's capex decreased by 36.8% year-over-year, from $1.26M to $796K.
- What is the long-term trend for Adaptive Biotechnologies's capex?
- Over 4 years (2021 to 2025), Adaptive Biotechnologies's capex has grown at a -53.2% compound annual growth rate (CAGR), from $61.75M to $2.96M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Adaptive Biotechnologies's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude